FUNDAMENTALS · Fundamentals · US Healthcare

Nektar Therapeutics (NKTR) Fundamentals 2026 — Revenue Analysis | SniperIQ

Nektar Therapeutics (NKTR) is a US-listed Healthcare company in Biotechnology with a market capitalization of

.3B, trading at $69.02 on the NASDAQ. This SniperIQ fundamentals page covers Nektar Therapeutics's valuation, profitability (net margin -284.2%), revenue ($55M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.

Market Cap
.3B
Net Margin-284.2%
Revenue (FY25)$55M

Full research coverage

  • 8-Quarter Revenue & Margin Trend
  • Debt Maturity & Coverage
  • Peer Valuation Comparison
  • Free Cash Flow & Owner Earnings
  • AI Signal + Institutional Flow
  • DCF Valuation Model

Frequently Asked Questions

What is Nektar Therapeutics's market cap?

Nektar Therapeutics (NKTR) has a market capitalization of approximately

.3B, trading at $69.02 on the NASDAQ. Market cap moves with the live share price.

What is Nektar Therapeutics's P/E ratio?

Nektar Therapeutics's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 3.0x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is Nektar Therapeutics?

Nektar Therapeutics runs a net profit margin of -284.2%, a gross margin of 99.4%, and an operating margin of -224.9%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does Nektar Therapeutics generate?

Nektar Therapeutics reported revenue of $55M for fiscal year 2025, with net income of -

64M and earnings per share (EPS) of -9.73. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does Nektar Therapeutics pay a dividend?

Nektar Therapeutics does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.

Is Nektar Therapeutics financially healthy?

Nektar Therapeutics carries a debt-to-equity ratio of 0.25x and a current ratio of 10.21x, with a market beta of 1.14. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is Nektar Therapeutics a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Nektar Therapeutics (NKTR) the key facts are: market cap

.3B, revenue $55M, 52-week range 21.02-109. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.

Track Nektar Therapeutics's full fundamentals live

Get Nektar Therapeutics's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.

Related: Phibro Animal Health (PAHC) fundamentals · SinoMab BioScience (3681) fundamentals · Absci (ABSI) fundamentals · Recursion Pharmaceuticals (RXRX) fundamentals · All stock fundamentals · AI signal library
Research Hubs: Fundamentals library · Screeners · Institutional positioning · Super investors · Daily signals · Platform comparisons